To address this fundamental question, we first performed cancer stem cell marker profile analysis using human breast cancer cell lines and specimens to further define and characterize different stem cell populations by flow cytometry, along with in vitro and in vivo assays to verify the stem cell properties of different cell isolates.
To investigate whether breast cancer cells freshly derived from clinical specimens express heterogeneous stem cell markers as observed in human breast cancer cell lines, we performed stem cell marker profiling by FACS analysis of nineteen specimens obtained from National Taiwan University Hospital.
Global marker genes expression and miRNAs profiling analysis provided insights into the regulation network of the topography induced MSCs' cell responses including adhesion, proliferation, differentiation and apoptosis.
Several of the selected markers listed above (ie, IL-6, IL-8, ICAM-1, MMP-3, TNFα and VEGF) were analysed as individual markers as well as being included in the protein profiling analysis.
In the present study, we used ploidy-based genetic analysis combined with tumour/stroma discrimination and CSC-associated marker profiling and found that glioma CSC marker expression does not define a genetically unique tumour clone.
Gene profiling analysis showed increased expression of adult CICs markers, genes involved in DNA double-strand breaks (DSB) repair and genes involved in an epithelial to mesenchymal transition.
Gene profiling analysis of HeLa and SiHa spheroid cells showed up-regulation of CICs markers characteristic of the female reproductive system.
Our profiling analysis indicates that all three stem/progenitor enriched subsets contain substantial numbers of known markers of murine PSC, namely Trp63, Cd200, Ctnnb1, Smo, Krt5, Krt14, Itga6/Cd49f, Cd44, Kit, Bcl2, and Cd34 [10] (Figure 2A, B, Table S4).
CP performed additional amplicon-specific marker profiling.
